iiinova — where your digital self keeps evolving

Victor Ferreira, PhD @victorhferreira.bsky.social · 05/02/2026

Our proposal to explore human cytomegalovirus (HCMV) disease pathogenesis in lung transplant recipients has been funded by CIHR! 🎉 I will be hiring 1 MSc and 1 PhD student for Fall 2026. Students can apply through LMP or IMS. Interested? Send your CV & transcript to victor.ferreira@uhn.ca.

020

Victor Ferreira, PhD @victorhferreira.bsky.social · 27/01/2026

My lab is looking for a post-doctoral fellow (PDF) to work on an exciting new translational immunology project developing and testing virus-specific T cell therapies for ex vivo organ perfusion and transplantation. Apply here ⤵️ jobs.smartrecruiters.com/UniversityHe...

jobs.smartrecruiters.com

Postdoctoral Researcher

Company Description: UHN is Canada’s #1 hospital and the world’s #1 publicly funded hospital. With 10 sites and more than 44,000 TeamUHN members, UHN consists of Toronto General Ho...

000

Victor Ferreira, PhD @victorhferreira.bsky.social · 10/11/2025

Today is my 11th year anniversary at @uhnresearch.ca! Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.

110

Victor Ferreira, PhD @victorhferreira.bsky.social · 29/09/2025

Our first publication addressing RSV vaccination in transplant recipients is now available in Clinical Microbiology and Infection: www.sciencedirect.com/science/arti... We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.

sciencedirect.com

Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study

Allogeneic hematopoietic cell transplant (alloHCT) and lung transplant (LT) recipients are at highest risk for severe respiratory syncytial virus (RSV…

121

Victor Ferreira, PhD @victorhferreira.bsky.social · 28/03/2025

Our latest work 🚨 a first-in-human study: We show that rituximab delivery via ex vivo lung perfusion is feasible and safe. With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation. journals.lww.com/transplantat...

journals.lww.com

Feasibility and Safety of Ex Vivo Delivery of Rituximab to... : Transplantation Direct

virus (EBV)-seropositive donors for transplantation into EBV-seronegative recipients (D+/R–) to reduce the risk of EBV-associated posttransplant lymphoproliferative disorder (PTLD), which remains a ma...

000

Reposted by Victor Ferreira, PhD

University Health Network @uhn.ca · 26/02/2025

UHN, Canada’s top hospital, is ranked third in the world for the second year in a row by @newsweek.com! This 2025 ranking solidifies UHN’s Toronto General Hospital as the top publicly-funded hospital in the world. Read the full report here: www.newsweek.com/rankings/wor...

02712

Reposted by Victor Ferreira, PhD

American Journal of Transplantation @amjtransplant.bsky.social · 24/02/2025

In Press and Open Access! "Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients" by Azarfar et al. buff.ly/43u19aH @victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination

011

Victor Ferreira, PhD @victorhferreira.bsky.social · 15/01/2025

Can anyone shed light on the new CIHR rankings? Is it safe to assume that all projects that rank in top 10% will be funded? Do we expect that some applications in the 11-25% rank will also be funded?

100

Reposted by Victor Ferreira, PhD

JAMA @jama.com · 30/12/2024

While immunocompromised individuals had a heterogeneous antibody response to RSV vaccines, those who received the adjuvanted RSVPreF3-AS01 vaccine showed better neutralization. ja.ma/4iVzJzy

Figure. Antibody Responses Among Immunocompromised Adults Following Respiratory Syncytial Virus (RSV) Vaccination

0239

Reposted by Victor Ferreira, PhD

Hensley Lab @scottehensley.bsky.social · 05/12/2024

Excellent study by my Penn-CEIRR colleagues showing that a single HA substitution in H5 (at same exact residue that changed in the British Columbia case!) enables efficient H5N1 binding to receptors in the human upper airway. www.science.org/doi/10.1126/...

science.org

A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors

In 2024, several human infections with highly pathogenic clade 2.3.4.4b bovine influenza H5N1 viruses in the United States raised concerns about their capability for bovine-to-human or even human-to-h...

48844

Victor Ferreira, PhD @victorhferreira.bsky.social · 05/12/2024

Can machine learning be used to predict SARS-CoV-2 vaccine responses in immunocompromised transplant recipients one year after their first dose of vaccine? Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.

tinyurl.com

Using Machine Learning for Personalized Prediction of Longitudinal COVID-19 Vaccine Responses in Transplant Recipients

The COVID-19 pandemic has underscored the importance of vaccines, especially for immunocompromised populations like solid organ transplant (SOT) recip…

110

Victor Ferreira, PhD @victorhferreira.bsky.social · 26/11/2024

Pleased to share that our project (led by Victoria Hall, Atul Humar, Deepali Kumar, and myself) was one of 35 selected for funding to address the risk of avian influenza in Canada. We will study H5 vaccine responses & safety in immunocompromised transplant recipients. www.canada.ca/en/institute...

canada.ca

Government of Canada invests in research on avian influenza A(H5N1) - Canada.ca

Avian influenza A(H5N1), commonly known as bird flu, is a viral disease that is typically transmitted between wild birds and poultry but can spread to other birds and mammals. Based on current evidenc...

010